UK AbbVie case augurs single EU medicines market
This article was originally published in Scrip
A victory in the UK Court of Appeal for parallel trader Chemistree against AbbVie could be a step towards a European single market for pharmaceuticals and help reduce drug shortages, said the law firm that represents Chemistree, Matthew Arnold & Baldwin. The case could have important ramifications for EU competition law and how pharma firms manage their supply chains.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.